Effectiveness of Fingolimod versus Natalizumab as Second-Line Therapy for Relapsing-Remitting Multiple Sclerosis in Spain: Second-Line GATE Study

被引:9
|
作者
Meca-Lallana, Jose [1 ,2 ]
Ayuso, Teresa [3 ]
Martinez-Yelamos, Sergio [4 ]
Duran, Carmen [5 ]
Contreras Martin, Yessica [6 ]
Herrera Navarro, Nicolas [7 ]
Perez Sempere, Angel [8 ]
Alvarez-Cermeno, Jose C. [9 ]
Millan Pascual, Jorge [10 ]
Meca-Lallana, Virginia [11 ]
Romero Sevilla, Raul [12 ]
Ricart, Javier [12 ]
机构
[1] Hosp Clin Univ Virgen Arrixaca IMIB ARRIXACA, Serv Neurol, Unidad Esclerosis Multiple, Murcia, Spain
[2] Univ Catolica San Antonio, UCAM, Catedra Neuroinmunol Clin & Esclerosis Multiple, Murcia, Spain
[3] Hosp Navarra, Pamplona, Spain
[4] Hosp Bellvitge Princeps Espanya, Lhospitalet De Llobregat, Spain
[5] Hosp Univ Infanta Cristina, Badajoz, Spain
[6] Hosp Univ Nuestra Senora Candelaria, Santa Cruz De Tenerife, Spain
[7] Hosp Burgos, Burgos, Spain
[8] Hosp Gen Alicante, Alicante, Spain
[9] Hosp Univ Ramon y Cajal, IRYCIS, Madrid, Spain
[10] Complejo Hosp La Mancha Ctr, Alcazar De San Juan, Spain
[11] Hosp Univ Princesa, Unidad Enfermedades Desmielinizantes, Madrid, Spain
[12] Novartis Farmaceut SA, Barcelona, Spain
关键词
Multiple sclerosis; Second-line treatment; Effectiveness; Fingolimod; Natalizumab; PLACEBO-CONTROLLED TRIAL; OPTIONS;
D O I
10.1159/000505778
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: There is a lack of head-to-head studies comparing the efficacy of fingolimod (FIN) and natalizumab (NTZ) as second-line therapy for relapsing-remitting multiple sclerosis (RRMS). Methods: Multicenter, observational study, in which, information of 388 patients randomly selected and treated with FIN or NTZ in routine clinical practice was retrospectively collected with the main objective of comparing the annualized relapse rate (ARR) over the first year, after FIN or NTZ treatment initiation. Results: Mean ARR during the first year of treatment was 0.28 in FIN group and 0.12 in NTZ group (p = 0.0064); nevertheless, the difference between groups lost statistical significance when the propensity score analysis was performed. Time to disability -progression was similar in both treatment groups (12.3 +/- 6.7 months in FIN, and 12.8 +/- 0.1 months in NTZ; p = 0.4654). Treatment persistence after the first year of treatment was higher in patients treated with FIN (95%) than in those treated with NTZ (84%; p = 0.0014). Conclusions: After 12 months of treatment, both FIN and NTZ reduced the ARR, but ARR percent reduction was significantly higher with NTZ. Treatment persistence was higher in patients receiving FIN.
引用
收藏
页码:25 / 33
页数:9
相关论文
共 50 条
  • [1] Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lorscheider, Johannes
    Benkert, Pascal
    Lienert, Carmen
    Hanni, Peter
    Derfuss, Tobias
    Kuhle, Jens
    Kappos, Ludwig
    Yaldizli, Ozgur
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (06) : 777 - 785
  • [2] Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab
    Bianco, Assunta
    Patanella, Agata Katia
    Nociti, Viviana
    Marti, Alessandro
    Frisullo, Giovanni
    Plantone, Domenico
    De Fino, Chiara
    Fetta, Anna
    Batocchi, Anna Paola
    Rossini, Paolo Maria
    Mirabella, Massimiliano
    EUROPEAN NEUROLOGY, 2015, 73 (1-2) : 57 - 65
  • [3] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    SWISS MEDICAL WEEKLY, 2016, 146 : 49S - 49S
  • [4] Lower relapse rates with natalizumab as compared with fingolimod as second-line treatment in relapsing-remitting multiple sclerosis
    Lienert, C.
    Benkert, P.
    Beer, S.
    Hanni, P.
    Pardini, M.
    D'Souza, M.
    Derfuss, T.
    Kuhle, J.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 627 - 627
  • [5] Are Natalizumab and Fingolimod Analogous Second-Line Options for the Treatment of Relapsing-Remitting Multiple Sclerosis? A Clinical Practice Observational Study
    Gajofatto, Alberto
    Bianchi, Maria Rachele
    Deotto, Luciano
    Benedetti, Maria Donata
    EUROPEAN NEUROLOGY, 2014, 72 (3-4) : 173 - 180
  • [6] Interim Analysis of the Effectiveness of Second-Line Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients Treated with Prior First-Line Treatment, Other Than Natalizumab, in Spain: The Observational, Retrospective NEXT Study
    Meca, Virginia
    Martinez, Marisa
    Jose Mallada, Javier
    Marzo, Eugenia
    Marzo, Eugenia
    Barrero, Francisco
    Javier Ricart, Francisco
    Garcia, Eli
    NEUROLOGY, 2016, 86
  • [7] AGGRESSIVE NATALIZUMAB TREATMENT FOR JC VIRUS-NEGATIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS? COST-EFFECTIVENESS OF FIRST-LINE VERSUS SECOND-LINE NATALIZUMAB TREATMENT
    McQueen, R. B.
    Nair, K., V
    Vollmer, T. L.
    Campbell, J. D.
    VALUE IN HEALTH, 2014, 17 (03) : A59 - A59
  • [8] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Stefan Braune
    M. Lang
    A. Bergmann
    Journal of Neurology, 2016, 263 : 327 - 333
  • [9] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
    Braune, Stefan
    Lang, M.
    Bergmann, A.
    JOURNAL OF NEUROLOGY, 2016, 263 (02) : 327 - 333
  • [10] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217